These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 367698)
41. A brief review of the development of diazoxide as an antihypertensive agent. Rubin AA; Taylor RM; Roth FE Ann N Y Acad Sci; 1968 Apr; 150(2):457-60. PubMed ID: 5243883 [No Abstract] [Full Text] [Related]
42. Hypertension: therapy as recommended by the national committees. Moyers JH Angiology; 1976 Feb; 27(2):71-90. PubMed ID: 1053475 [No Abstract] [Full Text] [Related]
43. The mechanisms of action of antihypertensive drugs. Abrams WB Dis Chest; 1969 Feb; 55(2):148-59. PubMed ID: 4887212 [No Abstract] [Full Text] [Related]
44. Björn Folkow Award Lecture. The sympathetic nervous system in hypertension. Mancia G J Hypertens; 1997 Dec; 15(12 Pt 2):1553-65. PubMed ID: 9488206 [No Abstract] [Full Text] [Related]
45. Individualization of antihypertensive therapy: an approach based on hemodynamics and age. Messerli FH J Clin Pharmacol; 1981; 21(11):517-28. PubMed ID: 7037869 [No Abstract] [Full Text] [Related]
46. Cyclosporine-induced hypertension in cardiac transplantation. Ventura HO; Mehra MR; Stapleton DD; Smart FW Med Clin North Am; 1997 Nov; 81(6):1347-57. PubMed ID: 9356603 [TBL] [Abstract][Full Text] [Related]
47. Heterogeneous pathophysiology of essential hypertension: implications for therapy. Messerli FH; Schmieder RE; Nunez BD Am Heart J; 1986 Oct; 112(4):886-93. PubMed ID: 3532746 [No Abstract] [Full Text] [Related]
48. [The effect of rauwopur on renal hemodynamics and on diuresis in animal experiment and in hypertension]. SZABO Z; NAGY Z Z Kreislaufforsch; 1960 Sep; 49():789-96. PubMed ID: 13774440 [No Abstract] [Full Text] [Related]
49. Monitoring of sympathetic activity in man: physiology and pharmacology. Grassi G; Seravalle G; Calhoun DA; Matturri M; Mancia G; Zanchetti A Eur Heart J; 1992 Jun; 13 Suppl A():22-5. PubMed ID: 1396847 [No Abstract] [Full Text] [Related]
50. The value of industry-sponsored studies of initial antihypertensive therapies. Caro JJ; Payne K CMAJ; 2001 Jun; 164(13):1832-3. PubMed ID: 11450276 [No Abstract] [Full Text] [Related]
51. Therapy for mild hypertension. Toward a more balanced view. Kaplan NM JAMA; 1983 Jan; 249(3):365-7. PubMed ID: 6336801 [No Abstract] [Full Text] [Related]
52. Development of the metabolic syndrome along the female biological life-path. Esler M; Wiesner G J Hypertens; 2006 Jan; 24(1):43-5. PubMed ID: 16331099 [No Abstract] [Full Text] [Related]
54. Selective inhibition of the sympathetic nervous system in man with bretylium tosylate, a new antihypertensive agent. FREIS ED; SUGIURA T; LIPTAK D Circulation; 1960 Aug; 22():191-7. PubMed ID: 13849851 [No Abstract] [Full Text] [Related]
58. Hypertension therapeutic research: a plea for change in the new millennium. Cohn JN Am J Hypertens; 2002 Jan; 15(1 Pt 1):97-8. PubMed ID: 11824868 [No Abstract] [Full Text] [Related]
59. [Arterial hypertension: an expanding pathogenic continuum and therapeutic limitations]. Kharchenko EP Ter Arkh; 2015; 87(1):100-104. PubMed ID: 25823277 [TBL] [Abstract][Full Text] [Related]